All News

Pharmacist intervention on drug-related problems in HIV outpatients can alleviate adherence issues.

Top news of the day from across the healthcare landscape.

Most patients on opioids experience one if not more adverse events, many gastrointestinal, during the course of therapy.

This article will describe the unusual discovery of 5 commonly prescribed medications, many of which were through serendipitous events.

Eculizumab is an injection that is associated with an increased risk of meningococcal disease.

When I first interviewed a pharmacist about her pharmacy position for my column, I found what I was meant to do and what I love to do: tell stories.

Top articles of the week from The American Journal of Pharmacy Benefits.

Maviret is an 8-week treatment that combines 2 distinct antiviral agents.

Isomeric allegedly manufactured and distributed purportedly sterile drug products, including injectable and ophthalmic drugs that were adulterated because the drugs were made under insanitary conditions.

Officials with the US Drug Enforcement Administration (DEA) have proposed to cut the amount of controlled substances to be manufactured in 2018 by 20%, compared to 2017, according to a press release.

Rebecca Shanahan, JD, chief executive officer of Avella Specialty and president of the National Association of Specialty Pharmacy speaks about DIR fees in a 3-part interview.

BACE inhibitors observed to reduce amyloid production and accumulation in the brain.

The American Diabetes Association and the American Association of Diabetes Educators report seeks to improve self-care and management of the chronic condition.

Top news of the week from Specialty Pharmacy Times.

If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.

Pilot project to bring pre-exposure prophylaxis to the Philippines for the first time.

A look at last week's top stories in the world of pharmacy.

Top news of the day from across the health care landscape.

Durvalumab is indicated to treat patients with locally-advanced, unresectable non-small cell lung cancer.

Targeting cell mutations could disrupt tumor cell growth without harming non-cancerous cells.

Less than half of patients who experience a stroke receive a statin prescription.

HIV-positive patients may not remain adherent to antiretroviral therapy and feminizing hormone therapy due to concerns over drug interactions.

Top news of the day from across the healthcare landscape.

To combat the abuse and diversion of opioid medications, Attorney General Jeff Sessions has announced the formation of a new Department of Justice (DOJ) pilot program to crack down on opioid-related health care fraud.

A look at the top stories in pharmacy last week.

Although the FDA is not bound by the recommendation of the committee, their advice is taken into consideration.

Officials with the FDA have announced the approval of glecaprevir and pibrentasvir (Mavyret, AbbVie Inc) for hepatitis C.

Mavyret approved for chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis.

Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.

Alectinib (Alcensa) reduced the risk of progression to the central nervous system by 84%.